<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004940</url>
  </required_header>
  <id_info>
    <org_study_id>199/13376</org_study_id>
    <secondary_id>BWH-FDR000996-DR</secondary_id>
    <nct_id>NCT00004940</nct_id>
  </id_info>
  <brief_title>Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:

      I. Determine the long-term efficacy and safety of L-cysteine in the prevention
      photosensitivity in patients with erythropoietic protoporphyria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a phase III study, lasting 3 years; 1996-1999. Patients are
      administered L-cysteine orally twice daily, 2 capsules with breakfast and 2 with lunch.

      Patients fill in questionnaires and diary sheets about their reaction to sunlight exposure,
      and have blood tested 3 times a year.

      Completion date provided represents the completion date of the grant per OOPD records
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1996</start_date>
  <completion_date>September 2001</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>50</enrollment>
  <condition>Erythropoietic Protoporphyria</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cysteine hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Erythropoietic protoporphyria RBC protoporphyrin greater than 50 micrograms/100 dL

        --Prior/Concurrent Therapy--

        At least 3 months since prior betacarotene or L-cysteine

        No concurrent betacarotene

        --Patient Characteristics--

          -  Fertile female patients must use effective contraception for duration of trial and for
             3 weeks thereafter

          -  Not pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Micheline Mary Mathews-Roth</last_name>
    <role>Study Chair</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <verification_date>April 2000</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>erythropoietic protoporphyria</keyword>
  <keyword>inborn errors of metabolism</keyword>
  <keyword>porphyria</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protoporphyria, Erythropoietic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

